keyword
MENU ▼
Read by QxMD icon Read
search

colorectal cancer chemotherapy

keyword
https://www.readbyqxmd.com/read/28441737/commitment-of-scaffold-proteins-in-the-onco-biology-of-human-colorectal-cancer-and-liver-metastases-after-oxaliplatin-based-chemotherapy
#1
Deborah Rotoli, Manuel Morales, Julio Ávila, María Del Carmen Maeso, María Del Pino García, Ali Mobasheri, Pablo Martín-Vasallo
Scaffold proteins play pivotal roles in the regulation of signaling pathways, integrating external and internal stimuli to various cellular outputs. We report the pattern of cellular and subcellular expression of scaffoldins angiomotin-like 2 (AmotL2), FK506 binding protein 5 (FKBP51) and IQ motif containing GTPase-activating protein 1 (IQGAP1) in colorectal cancer (CRC) and metastases in liver resected after oxaliplatin-based chemotherapy (CT). Positive immunostaining for the three scaffoldins was found in most cells in healthy colon, tumor, healthy liver and metastasized liver...
April 22, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28441110/effects-of-the-us-food-and-drug-administration-boxed-warning-of-erythropoietin-stimulating-agents-on-utilization-and-adverse-outcome
#2
John Bian, Brian Chen, Dawn L Hershman, Norman Marks, LeAnn Norris, Richard Schulz, Charles Bennett
Purpose In March 2007, a US Food and Drug Administration boxed warning was issued for erythropoietin-stimulating agents (ESAs) regarding serious adverse events, such as venous thromboembolism (VTE). We evaluated the US Food and Drug Administration's boxed warning of ESAs used to treat chemotherapy-induced anemia because evidence on the effectiveness of boxed warnings remains inconclusive. Patients and Methods Using 2004 to 2009 SEER-Medicare data, we exploited a natural experiment to examine the effects of ESA boxed warnings on utilization and risk of VTE...
April 25, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28440086/debiri-plus-capecitabine-a-treatment-option-for-refractory-liver-dominant-metastases-from-colorectal-cancer
#3
Vincenzo Di Noia, Michele Basso, Valentina Marsico, Eleonora Cerchiaro, Sabrina Rossi, Ettore D'Argento, Antonia Strippoli, Giovanni Schinzari, Roberto Iezzi, Alessandra Cassano, Carlo Barone
AIM: This single institution Phase II study evaluated drug-eluting beads loaded with irinotecan (DEBIRI) plus capecitabine in pretreated patients with colorectal cancer liver metastases. PATIENTS & METHODS: Forty patients with liver-limited or liver-dominant disease, who have failed at least two previous lines of chemotherapy, underwent either four DEBIRI at 2-week interval or two DEBIRI every 4 weeks for bilobar or single-lobe metastases, respectively. Capecitabine was given at 1000 mg/m(2) twice daily on days 1-14 every 3 weeks...
April 25, 2017: Future Oncology
https://www.readbyqxmd.com/read/28435250/sl2b-aptamer-and-folic-acid-dual-targeting-dna-nanostructures-for-synergic-biological-effect-with-chemotherapy-to-combat-colorectal-cancer
#4
Pengchao Sun, Nan Zhang, Yafang Tang, Yanan Yang, Xiao Chu, Yongxing Zhao
DNA nanostructures prepared by self-assembly possess good stability, high biocompatibility, and low immunogenicity as drug delivery vehicles. In this work, DNA tetrahedron (TD) was constructed and modified with SL2B aptamer (S) and folic acid (F). TD possessed a small diameter (~6 nm) and entered into the nucleus quickly. SL2B aptamer can inhibit cancer cell growth by disturbing vascular endothelial growth factor/Notch signaling pathways. To explore the effect of SL2B number on colorectal cancer inhibition, SL2B multimers (dimer, trimer, and tetramer) were constructed by functionalization of TD with different numbers of SL2B...
2017: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/28434884/neurotoxicity-outcomes-in-a-population-based-cohort-of-elderly-patients-treated-with-adjuvant-oxaliplatin-for-colorectal-cancer
#5
Michael J Raphael, Hadas D Fischer, Kinwah Fung, Peter C Austin, Geoffrey M Anderson, Christopher M Booth, Simron Singh
BACKGROUND: The addition of oxaliplatin to adjuvant treatment regimens for colorectal cancer has been shown to improve overall survival at the expense of increased toxicity. The incidence and severity of toxicity might be greater among older patients who might also derive less benefit from oxaliplatin. We evaluated the association between adjuvant oxaliplatin-based chemotherapy and neurotoxicity outcomes in an elderly cohort of patients. PATIENTS AND METHODS: A population-based cohort of patients aged > 65 years with stage II and III colorectal cancer treated with adjuvant therapy in Ontario, Canada was identified using the Ontario Cancer Registry...
March 24, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28434582/effectiveness-between-early-and-late-temporary-ileostomy-closure-in-patients-with-rectal-cancer-a-prospective-study
#6
Li Zhen, Yanan Wang, Ze Zhang, Tongwei Wu, Ruoyan Liu, Tingting Li, Liying Zhao, Haijun Deng, Xiaolong Qi, Guoxin Li
A temporary stoma is often used in rectal cancer surgery to protect a distal anastomosis, which remains a major concern after rectal cancer surgery, particularly after low anterior resection. The temporary stoma is scheduled for closure. However, the optimal time of closure of the protecting stoma remains unclear because of sparse studies and data. We aimed to detect the efficacy between early and late temporary ileostomy closure in patients with rectal cancer during or after neoadjuvant chemoradiotherapy. We conducted a prospective, 2-group design between early and late ileostomy closure group in patients after rectal cancer surgery with temporary stoma...
March 2, 2017: Current Problems in Cancer
https://www.readbyqxmd.com/read/28433602/folfoxiri-regimen-for-metastatic-colorectal-cancer-a-systematic-review-and-meta-analysis
#7
Frederico Leal, Fernanda Proa Ferreira, Andre Deeke Sasse
INTRODUCTION: Cytotoxic chemotherapy is the mainstay treatment for metastatic colorectal cancer (mCRC). Fluoropyrimidines, oxaliplatin, and irinotecan are the most active drugs; however, their optimal sequencing has not yet been established. Some evidence has shown that upfront treatment with 5-fluorouracil, oxaliplatin, and irinotecan (FOLFOXIRI regimen) can improve outcomes for patients with mCRC. MATERIALS AND METHODS: We performed a systematic search in electronic databases...
March 24, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28433600/hepatic-arterial-infusion-chemotherapy-for-unresectable-liver-metastases-of-colorectal-cancer-a-multicenter-retrospective-study
#8
REVIEW
Annie Lim, Samuel Le Sourd, Hélène Senellart, Dominique Luet, Frédéric Douane, Christophe Perret, Antoine Bouvier, Sylvie Métairie, Estelle Cauchin, Philippe Rougier, Tamara Matysiak-Budnik, Yann Touchefeu
Hepatic arterial infusion chemotherapy (HAIC) is a treatment used for liver metastases (LM) of colorectal cancer (CRC). Because of its technical conditions, it has been used in only a few experienced centers in France. Our aim was to evaluate its feasibility, efficacy and tolerance in 4 centers. Clinical, biological, and radiological data of patients treated with HAIC for unresectable LM from CRC in 4 institutions from October 2011 to January 2016 were retrospectively analyzed. Sixty-one patients with unresectable LM from CRC were included...
March 14, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28431950/postoperative-adjuvant-chemotherapy-is-associated-with-a-lower-incidence-of-colorectal-adenomas-in-patients-with-previous-colorectal-cancer
#9
Hee Seung Lee, Sung Bae Kim, Hyun Jung Lee, Soo Jung Park, Sung Pil Hong, Jae Hee Cheon, Won Ho Kim, Tae Il Kim
BACKGROUND AND AIMS: The effects of chemotherapeutic agents on the development of colorectal adenomas in patients with previous colorectal cancer (CRC) are not defined. Therefore, we evaluated the potential effect of adjuvant chemotherapy on the incidence of colorectal adenomas in patients with previous CRC. METHODS: We selected patients with low-risk stage II CRC with or without postoperative 5-fluorouracil-based adjuvant chemotherapy to reduce selection bias. Among 1808 patients with stage II CRC who underwent colonoscopic surveillance after curative resection of CRC between 2006 and 2013, 192 patients were retrospectively enrolled in this study after matching for age and sex...
April 18, 2017: Gastrointestinal Endoscopy
https://www.readbyqxmd.com/read/28430643/lymph-node-status-as-a-prognostic-factor-after-palliative-resection-of-primary-tumor-for-patients-with-metastatic-colorectal-cancer
#10
Qingguo Li, Changjian Wang, Yaqi Li, Xinxiang Li, Ye Xu, Guoxiang Cai, Peng Lian, Sanjun Cai
Lymph node (LN) status is one of the most important predictors for M0 colorectal cancer patients. However, its clinical impact on stage IV colorectal cancer remains unclear. The study aimed to explore the prognostic value of LN status after palliative resection of primary tumor for patients with metastatic colorectal cancer (mCRC). We combined analyses of mCRC patients in Surveillance, Epidemiology and End Results (SEER) database and Fudan University Shanghai Cancer Center (FUSCC).A total of 17,553 patients with mCRC were identified in SEER database...
February 25, 2017: Oncotarget
https://www.readbyqxmd.com/read/28428512/-change-of-blood-neutrophil-to-lymphocyte-ratio-predicts-survival-in-patients-with-metastatic-colorectal-cancer
#11
Katsuki Muneoka, Yoshio Shirai, Masataka Sasaki, Jun Sakata, Junkichi Kanda, Hiroyuki Wakabayashi, Toshifumi Wakai
AIM: The impact of neutrophil-to-lymphocyte ratio(NLR)changes on the outcome of chemotherapy for metastatic colorectalcancer (mCRC)was analyzed retrospectively. METHODOLOGY: Twenty seven patients with unresectable mCRC were administered chemotherapy from January 2005 to December 2014 at the Niitsu Medical Center Hospital. The NLR was calculated from complete blood counts obtained prior to the administration of chemotherapy and at the best response. We defined the period with NLR≤2...
April 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28426981/overall-survival-in-elderly-patients-with-colorectal-cancer-a-population-based-study-in-the-caribbean
#12
Clarisse Joachim, Lidvine Godaert, Moustapha Dramé, Jacqueline Véronique-Baudin, Jonathan Macni, Juliette Smith-Ravin, Jean-Luc Novella, Rachid Mahmoudi
BACKGROUND: Population-based Cancer registries (PBCR) play an important role in cancer surveillance and research. The aim of this study was to examine overall survival in elderly patients with colorectal cancer (CRC) by analysing data from the Martinique PBCR between 1993 and 2012. METHODS: The log-rank test was used to assess the statistical differences of the survival curves by each categorical variable: age at diagnosis, sex, histology, zone of residence, subsite, stage at diagnosis, and chemotherapy...
April 17, 2017: Cancer Epidemiology
https://www.readbyqxmd.com/read/28426374/perioperative-hepatic-arterial-infusion-pump-chemotherapy-is-associated-with-longer-survival-after-resection-of-colorectal-liver-metastases-a-propensity-score-analysis
#13
Bas Groot Koerkamp, Eran Sadot, Nancy E Kemeny, Mithat Gönen, Julie N Leal, Peter J Allen, Andrea Cercek, Ronald P DeMatteo, T Peter Kingham, William R Jarnagin, Michael I D'Angelica
Purpose To investigate whether perioperative hepatic arterial infusion pump chemotherapy (HAI) was associated with overall survival (OS) in patients who had a complete resection of colorectal liver metastases (CLM). Methods Patients who underwent a complete resection of CLM between 1992 and 2012 were included from a single-center prospectively maintained database. All patients who received HAI also received perioperative systemic chemotherapy. Propensity score analysis was used to match patients for seven known prognostic factors...
April 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28422714/toll-like-receptor-3-as-an-immunotherapeutic-target-for-kras-mutated-colorectal-cancer
#14
Radhashree Maitra, Titto Augustine, Yitzchak Dayan, Carol Chandy, Matthew Coffey, Sanjay Goel
New therapeutic interventions are essential for improved management of patients with metastatic colorectal cancer (mCRC). This is especially critical for those patients whose tumors harbor a mutation in the KRAS oncogene (40-45% of all patients). This patient cohort is excluded from receiving anti-EGFR monoclonal antibodies that have added a significant therapeutic benefit for KRAS wild type CRC patients. Reovirus, a double stranded (ds) RNA virus is in clinical development for patients with chemotherapy refractory KRAS mutated tumors...
April 4, 2017: Oncotarget
https://www.readbyqxmd.com/read/28422287/genetic-variants-as-potential-predictive-biomarkers-in-advanced-colorectal-cancer-patients-treated-with-oxaliplatin-based-chemotherapy
#15
REVIEW
Afsane Bahrami, Forouzan Amerizadeh, Seyed Mahdi Hassanian, Soodabeh ShahidSales, Majid Khazaei, Mina Maftouh, Majid Ghayour-Mobarhan, Gordon A Ferns, Amir Avan
Chemotherapy regimen containing oxaliplatin is often the first-line treatment for patient with advanced colorectal cancer. Oxaliplatin binds to DNA, leading to the formation of crosslinks and bulky adducts. Approximately 50% of patients with CRC benefit from treatment with oxaliplatin. It is possible that genetic variants in biological pathways involved in drug transportation, drug metabolism, DNA damage repair, and cell cycle modulation might affect the activity, or efficacy of oxaliplatin. Because oxaliplatin resistance may be related to these genetic variants and may therefore be an important reason for treatment failure, we have summarized the genetic variations that have been reported to be predictive markers of the response to oxaliplatin based therapy in patients with advanced CRC...
April 19, 2017: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/28422250/a-novel-nanomissile-targeting-two-biomarkers-and-accurately-bombing-ctcs-with-doxorubicin
#16
Yu Gao, Xiaodong Xie, Fengqiao Li, Yusheng Lu, Tao Li, Shu Lian, Yingying Zhang, Huijuan Zhang, Hao Mei, Lee Jia
Rare circulating tumor cells (CTCs) cause >50% of primary colorectal cancer survivors to develop deadly metastasis at 3-5 years after surgery; the current chemotherapies can do nothing about these cells. Herein, we synthesized a novel doxorubicin (DOX)-entrapped mesoporous silica nanoparticle (MSN), covalently-conjugated with two aptamers, for simultaneously targeting EpCAM and CD44, the typical surface biomarkers of colorectal CTCs. The nanomissile can specifically capture the metastasis-prone CTCs spiked in healthy human blood in a competitive-binding manner...
April 19, 2017: Nanoscale
https://www.readbyqxmd.com/read/28419195/plasma-ctdna-ras-mutation-analysis-for-the-diagnosis-and-treatment-monitoring-of-metastatic-colorectal-cancer-patients
#17
J Vidal, L Muinelo, A Dalmases, F Jones, D Edelstein, M Iglesias, M Orrillo, A Abalo, C Rodríguez, E Brozos, Y Vidal, S Candamio, F Vázquez, J Ruiz, M Guix, L Visa, V Sikri, J Albanell, B Bellosillo, R López, C Montagut
Background: RAS assessement is mandatory for therapy decision in metastatic colorectal cancer (mCRC) patients. This determination is based on tumor tissue, however genotyping of circulating tumor (ct)DNA offers clear advantages as a minimally invasive method that represents tumor heterogeneity. Our study aims to evaluate the use of ctDNA as an alternative determining baseline RAS status and subsequent monitoring of RAS mutations during therapy as a component of routine clinical practice...
April 13, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28418176/panitumumab-conjugated-pt-drug-nanomedicine-for-enhanced-efficacy-of-combination-targeted-chemotherapy-against-colorectal-cancer
#18
Ming-Hsien Tsai, Chao-Hsuan Pan, Cheng-Liang Peng, Ming-Jium Shieh
Targeted combination chemotherapy (TCT) has recently been used to increase the induction of tumor cell death. In particular, the combination of Panitumumab and the platinum (Pt)-derived chemotherapeutic drug Oxaliplatin is clinically effective against KRAS and BRAF wild-type colorectal cancer (CRC) cells that overexpress epidermal growth factor receptors, and significantly greater efficacy is observed than with either drug alone. However, low accumulation of Pt drug in tumor sites prevents achievement of ideal efficacy...
April 18, 2017: Advanced Healthcare Materials
https://www.readbyqxmd.com/read/28415828/melatonin-for-the-prevention-and-treatment-of-cancer
#19
REVIEW
Ya Li, Sha Li, Yue Zhou, Xiao Meng, Jiao-Jiao Zhang, Dong-Ping Xu, Hua-Bin Li
The epidemiological studies have indicated a possible oncostatic property of melatonin on different types of tumors. Besides, experimental studies have documented that melatonin could exert growth inhibition on some human tumor cells in vitro and in animal models. The underlying mechanisms include antioxidant activity, modulation of melatonin receptors MT1 and MT2, stimulation of apoptosis, regulation of pro-survival signaling and tumor metabolism, inhibition on angiogenesis, metastasis, and induction of epigenetic alteration...
March 18, 2017: Oncotarget
https://www.readbyqxmd.com/read/28415804/leucine-rich-alpha-2-glycoprotein-1-relevant-with-microvessel-density-is-an-independent-survival-prognostic-factor-for-stage-iii-colorectal-cancer-patients-a-retrospective-analysis
#20
De-Cong Sun, Yan Shi, Ling-Xiong Wang, Yao Lv, Quan-Li Han, Zhi-Kuan Wang, Guang-Hai Dai
BACKGROUND: Leucine-rich alpha-2-glycoprotein-1 (encoded by LRG1) has been shown to be involved in multiple cancer progression and angiogenesis. LRG1 has been shown to be one of the five plasma proteins that can be used for colorectal cancer (CRC) diagnosis. The objective of the current study was to explore relationship between LRG1 protein expression and microvessel density (MVD) in stage III CRC. METHODS: A single-center retrospective analysis of all stage III CRC who underwent surgery and adjuvant chemotherapy was carried out...
March 16, 2017: Oncotarget
keyword
keyword
40932
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"